Who are bezafibrate (drug)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lopid, Product 2 - AquaCelle Fish Oil Ethyl Ester, Statin plus fenofibrate, PUFAs, Lipanor, Lipavil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bezafibrate-drug.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

bezafibrate (drug) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

bezafibrate (drug) (bezafibrate (drug)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrate. Area: Cardiovascular.

phase 3 Fibrate PPAR-alpha Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

bezafibrate (drug) (bezafibrate (drug)) — Assistance Publique - Hôpitaux de Paris. Bezafibrate is a fibric acid derivative that activates peroxisome proliferator-activated receptor alpha (PPAR-alpha), leading to increased lipolysis and decreased lipogenesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
bezafibrate (drug) TARGET	bezafibrate (drug)	Assistance Publique - Hôpitaux de Paris	phase 3	Fibrate	PPAR-alpha
Lopid	Gemfibrozil	Pfizer Inc.	marketed	Peroxisome Proliferator Receptor alpha Agonist [EPC]	PPAR-alpha (Peroxisome Proliferator-Activated Receptor Alpha)
Product 2 - AquaCelle Fish Oil Ethyl Ester	Product 2 - AquaCelle Fish Oil Ethyl Ester	RDC Clinical Pty Ltd	marketed	Omega-3 fatty acid supplement / Triglyceride-lowering agent	Multiple targets including PPAR-alpha, GPR120, and hepatic lipid metabolism pathways
Statin plus fenofibrate	Statin plus fenofibrate	University of Ioannina	marketed	Combination lipid-lowering agent (statin + fibrate)	HMG-CoA reductase (statin component); PPAR-alpha (fenofibrate component)
PUFAs	PUFAs	Federal University of São Paulo	phase 3	Fatty acid	PPAR-alpha, PPAR-gamma
Lipanor	CIPROFIBRATE	Winthrop Pharmaceuticals UK Limited	marketed	ciprofibrate	Peroxisome proliferator-activated receptor alpha	1985-01-01
Lipavil	CLOFIBRATE		marketed	clofibrate	Peroxisome proliferator-activated receptor alpha	1967-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrate class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bezafibrate (drug) — Competitive Intelligence Brief. https://druglandscape.com/ci/bezafibrate-drug. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab